Technical Analysis for SGMO - Sangamo BioSciences, Inc.

Grade Last Price % Change Price Change
A 1.88 10.59% 0.18
SGMO closed up 10.59 percent on Friday, November 1, 2024, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up

Date Alert Name Type % Chg
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Calm After Storm Range Contraction 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
Upper Bollinger Band Walk Strength 10.59%
Earnings Movers Other 10.59%
Wide Bands Range Expansion 10.59%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 17 hours ago
Possible Inside Day about 17 hours ago
2x Volume Pace about 21 hours ago
Up 1 ATR about 21 hours ago
1.5x Volume Pace about 21 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Sangamo BioSciences, Inc. Description

Sangamo BioSciences, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of zinc finger DNA-binding proteins (ZFPs) for gene regulation and gene modification in the United States. Its ZFPs could be engineered to make ZFP nucleases (ZFNs) proteins, which could be used to modify DNA sequences in various ways; and ZFP transcription factors (ZFP TFs) proteins that could be used to turn genes on or off. The company's principal ZFP therapeutic is SB-728-T, a ZFN-modified autologous T-cell product, which is in Phase II and Phase I/II clinical trials for the treatment of human immunodeficiency virus and acquired immunodeficiency syndrome. It also develops SB-313xTZ that is in Phase I clinical trial for the treatment of glioblastoma. In addition, the company has ZFP therapeutic pre-clinical stage programs for hemophilia A and B, and huntington's disease; and proprietary programs in the areas of hemoglobinopathies and lysosomal storage disorders. Further, it has ZFP therapeutic research stage programs in the areas of other monogenic diseases, including certain immunodeficiency disorders. The company has collaboration, research, and license agreements with Shire AG; Sigma-Aldrich Corporation; Dow AgroSciences LLC; Genentech, Inc.; Open Monoclonal Technology, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. Sangamo Biosciences, Inc. was founded in 1995 and is headquartered in Richmond, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Emerging Technologies Molecular Biology Blastoma Glioblastoma Immunodeficiency Hemoglobin Huntington's Disease Hemophilia Transcription Transcription Factors Cell Product Monogenic Hemophilia A Lysosomal Storage Disorder Transcription Factor Lysosomal Storage Disorders Monogenic Diseases Deficiency Syndrome Dow Agrosciences Hemoglobinopathies Hoffmann La Roche

Is SGMO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.3
52 Week Low 0.2911
Average Volume 6,613,231
200-Day Moving Average 0.74
50-Day Moving Average 1.00
20-Day Moving Average 1.25
10-Day Moving Average 1.63
Average True Range 0.23
RSI (14) 70.76
ADX 40.42
+DI 31.90
-DI 12.28
Chandelier Exit (Long, 3 ATRs) 1.61
Chandelier Exit (Short, 3 ATRs) 1.43
Upper Bollinger Bands 2.16
Lower Bollinger Band 0.35
Percent B (%b) 0.85
BandWidth 143.89
MACD Line 0.28
MACD Signal Line 0.20
MACD Histogram 0.0781
Fundamentals Value
Market Cap 333.41 Million
Num Shares 177 Million
EPS -1.46
Price-to-Earnings (P/E) Ratio -1.29
Price-to-Sales 0.51
Price-to-Book 0.75
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.13
Resistance 3 (R3) 2.12 2.03 2.09
Resistance 2 (R2) 2.03 1.97 2.03 2.07
Resistance 1 (R1) 1.96 1.93 1.99 1.96 2.06
Pivot Point 1.87 1.87 1.88 1.87 1.87
Support 1 (S1) 1.79 1.80 1.83 1.80 1.70
Support 2 (S2) 1.70 1.76 1.70 1.69
Support 3 (S3) 1.63 1.70 1.67
Support 4 (S4) 1.63